title: Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma.
abstract: In this Eastern Cooperative Oncology Group (ECOG) phase II study, dibromodulcitol (DBD) and a combination of actinomycin D, hydroxyurea, and cyclophosphamide (AHC) were compared with methyl-CCNU, the current ECOG standard, in patients who had received no prior chemotherapy for disseminated malignant melanoma. The response rates were 6% (3/50) for AHC, 9% (3/34) for DBD, and 14% (7/49) for methyl-CCNU. Median survival times were 4, 5, and 6 months, respectively. Neither regimen appears to offer any advantage over methyl-CCNU as front-line therapy for patients with disseminated melanoma.
authors: Dana-Farber Cancer Institute, Boston, MA.
authors: D A
authors: DA
authors: Amato
authors: H
authors: H
authors: Bruckner
authors: D
authors: D
authors: Guerry
authors: A
authors: A
authors: Ash
authors: G
authors: G
authors: Falkson
authors: E C
authors: EC
authors: Borden
authors: R H
authors: RH
authors: Creech
authors: E D
authors: ED
authors: Savlov
authors: T J
authors: TJ
authors: Cunningham
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003609:Dactinomycin / Q000008:administration & dosage; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D008936:Mitolactol / Q000009:adverse effects / Q000627:therapeutic use*; D012673:Semustine / Q000627:therapeutic use
chemical_list: D012673:Semustine; D003609:Dactinomycin; D003520:Cyclophosphamide; D008936:Mitolactol; D006918:Hydroxyurea